Detalhe da pesquisa
1.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4073-4083, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459418
2.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer
; 153(1): 153-163, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883420
3.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33038277
4.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4121-4122, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38575722
5.
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321).
Front Oncol
; 13: 1272175, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37909020
6.
FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group.
J Clin Oncol
; 40(32): 3750-3761, 2022 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35709415
7.
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
J Clin Oncol
; 39(13): 1468-1478, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764808
8.
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Lancet Gastroenterol Hepatol
; 6(2): 128-138, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33338442
9.
Expression of tumor necrosis factor receptor-associated factor 1 in nasopharyngeal carcinoma: possible upregulation by Epstein-Barr virus latent membrane protein 1.
Int J Cancer
; 112(2): 265-72, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15352039